Pediatrics
From the Journals
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
Compared with adalimumab, JAK inhibitors presented no higher risk of major adverse cardiovascular events or venous thromboembolism in patients...
From the Journals
Increased body temperature triggers flares in rare autoinflammatory disorder
New mouse models that demonstrate how higher body temperature reduces levels of mevalonate kinase can serve as “preclinical platforms” to test the...
Latest News
Apremilast alleviates severe psoriasis in some children, data show
“In this randomized, placebo-controlled trial, oral apremilast demonstrated effectiveness and was well tolerated.”
Livin' on the MDedge
‘Dr. Caveman’ had a leg up on amputation
Plus: Walking your way to a quieter baby, lending a nose to Parkinson’s research, and identifying the office flirts.
20th Anniversary
OMERACT continues to set standards on research outcomes, enhancing the patient voice
OMERACT arose from a need to streamline clinical outcome measures in rheumatology, and now with 30 years of...
Latest News
VTE risk not elevated in AD patients on JAK inhibitors: Study
The labels of JAK inhibitors include a boxed warning describing an increased risk of “serious heart-related events such as heart attack or stroke...
News from the FDA/CDC
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.
From the Journals
Biosimilar-to-biosimilar switches deemed safe and effective, systematic review reveals
While switches between biosimilars of the same reference biologic already occur for biosimilars with indications in different specialties, they do...
Latest News
Experts: EPA should assess risk of sunscreens’ UV filters
The assessment is urgently needed and the results should be shared with the Food and Drug Administration, the experts said.
From the Journals
Stopping JIA drugs? Many can regain control after a flare
About 67% of patients who stopped medications for well-controlled JIA got their condition under control by 1 year after postflare treatment,...
Guidelines
ACR makes changes to adult, pediatric vaccinations guidance
The pneumococcal, recombinant zoster, and HPV vaccines are among those recommended for patients taking immunosuppressive medications.